Navigation Links
Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum
Date:4/17/2014

NEW YORK (17 April 2014) Population Council scientists and their partners have found that their proprietary microbicide gel is safe, stable, and can prevent the transmission of multiple sexually transmitted infections (STIs) in both the vagina and rectum in animals: HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study also provides the first data that the gel is effective against multiple strains of HIV, and has a window of efficacy in the vagina against all three viruses of at least eight hours prior to exposure. A Phase 1 safety trial of the gel is set to begin enrollment in May 2014.

These findings were published today in PLOS ONE in an article entitled "A Potent Combination Microbicide that Targets SHIV-RT, HSV-2 and HPV."

The gel, known as MZC, contains two potent antiviral agents: MIV-150 and zinc acetate. MIV-150 is an enzyme inhibitor that prevents HIV-infected cells from producing new virus, and zinc acetate is an antiviral agent with known activity against HIV and HSV-2. These compounds are mixed in a base of carrageenan, a compound derived from seaweed that has also been shown to have potent activity against HPV. Infection with HSV-2 or HPV is associated with increased risk of HIV infection. Microbicides that target HIV, HSV-2, and HPV may more effectively limit HIV transmission than those that target HIV alone.

In this study, Council scientists and their partners used macaque and mouse models to examine whether MZC gel could prevent the vaginal and rectal transmission of SHIV-RT, HSV-2, and HPV. SHIV-RT is a human/simian immunodeficiency chimeric virus combining the HIV reverse transcriptase (RT) within SIV (the monkey version of HIV). MIV-150 and zinc acetate inhibit HIV-RT via different mechanisms of action. Preclinical testing in animals is required by the FDA and is important to ensure the highest level of safety and to build the evidence base for potential efficacy in humans.

"It is the versatility of MZC that makes it a desirable microbicide candidate," said Jos A. Fernndez Romero, a scientist at the Population Council and corresponding author of the paper. "It is effective against multiple viruses, can be used in both the vagina and the rectum, and retains its efficacy in the vagina over an extended period of time. In addition to the gel, we are also exploring sustained-release intravaginal rings and on-demand film-based delivery systems for MZC. There is a growing demand for microbicides that prevent multiple STIs, and we are committed to ensuring that women and men have options when choosing what works most effectively for their own protection."


'/>"/>

Contact: Melanie Boyer
mboyer@popcouncil.org
202-237-9404
Population Council
Source:Eurekalert

Related medicine news :

1. Researchers develop a new cell and animal model of inflammatory breast cancer
2. FDA Seeks to Limit Antibiotics in Animal Feed
3. Animals More Interesting to Kids Than Toys, Study Shows
4. Raucous Music May Tap Into Your Inner Animal
5. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
6. Woodbridge Animal Hospital Unleashes New Pet Care Website
7. Chicago Dog Bite Injury Lawyers Advise Dog Owners To Get Control of Their Animals, Or Be Prepared To Pay Up
8. New technique could reduce number of animals needed to test chemical safety
9. Potential treatment target identified in an animal model of pancreatic cancer
10. New animal model may lead to treatments for common liver disease
11. Lab-engineered muscle implants restore function in animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , ... September 25, 2017 , ... ... today announced its latest release of SentinelSecure™, version 3.0, will be available in ... . This newest version of SentinelSecure™ comes with several new enhancements including support ...
(Date:9/25/2017)... ... September 25, 2017 , ... The Byron Eaton Agency, a Birmingham based firm ... is organizing a local charity drive to send money and support to families in ... water have fallen on Houston as a result of Hurricane Harvey, raising water levels ...
(Date:9/25/2017)... ... September 25, 2017 , ... Tim Rial Agency of Burleson, TX announces ... serves. By working closely with nonprofit groups and community leaders, the agency hopes to ... aid worthy organizations, families and individuals. , Tim Rial, the owner of Tim ...
(Date:9/25/2017)... PITTSBURGH, PA (PRWEB) , ... September 25, 2017 , ... ... efficient way to update patient charts in hospitals and medical facilities, so he invented ... to access and update patient charts. In doing so, it offers an improved alternative ...
(Date:9/25/2017)... (PRWEB) , ... September 25, ... ... of specialized science and technology-enabled services supporting clinical research, today announces that ... addressing key aspects of the drug development lifecycle at upcoming industry conferences ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... 2017 Caris Life Sciences, a leading ... promise of precision medicine, today announced results from ... its molecular profiling approach in guiding therapeutic strategies ... plus (CGP+) with Caris Molecular Intelligence ® ... molecular level, leading to more therapeutic options and ...
(Date:9/6/2017)...  Robert G. Szewc, M.D., is recognized by Continental ... of his contributions to the Medical field.      ... the practice of Kidney and Hypertension Specialists, which specializes ... solutions. He has worked in this position since 2002, ... well as expertise in kidneys, hypertension, chronic disease and ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology: